We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test for Plavix Users

By HospiMedica staff writers
Posted on 06 Oct 2005
A new blood test is designed to quickly and easily measure the effects of Plavix (clopidogrel) on platelets, which are primarily responsible for clotting.

Almost 10 million people in the United States alone take Plavix to help prevent a heart attack or stroke. More...
Inhibiting the function of platelets is how Plavix exerts its cardiovascular effects. However, new research shows that five-30% of patients do not respond adequately to the drug. People who are unresponsive are at much greater risk for a serious cardiovascular event as well as blockage of coronary stents. The VerifyNow P2Y12 test in less than 15 minutes can not only indicate nonresponders but also help determine if it is safe for some patients to undergo surgery.

"Plavix is a very effective medication for preventing strokes and heart attacks,” noted Mark Alberts, M.D., professor of neurology at Northwestern University Feinberg School of Medicine (Chicago, IL, USA). "However, in a certain percentage of patients, the blood thinning effects of Plavix may not be optimal. The VerifyNow test provides physicians with an important tool to help identify these patients and plan appropriate therapy.”

Medical guidelines recommend that patients stop taking Plavix five days prior to surgery in order to enable clotting function to return to normal and to reduce the risk of excessive bleeding during or after the operation. This means that surgery must often be delayed. The VerifyNow test was developed by Accumetrics (San Diego, CA, USA), which also manufactures and markets the test. The company notes that VerifyNow is the only rapid platelet function test shown to correlate with clinical outcomes.





Related Links:
Northwestern Feinberg
Accumetrics

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.